Apparent darkening of scalp hair related to pili multigemini Following dabrafenib and trametinib
- Author(s): Avila, Christina;
- Hoffman, Kalyn;
- Milani-Nejad, Nima;
- Pootrakul, Llana
- et al.
Published Web Locationhttps://doi.org/10.5070/D3261047194
The combination of dabrafenib and trametinib is an important immunotherapy option for patients with BRAF V600 mutation-positive melanoma. This regimen has been reported to cause cutaneous eruptions. However, hair dysmorphology is not a reported side effect to these or any other medications to date. Herein, we highlight a case of pili multigemini formation in a patient with stage IV melanoma receiving treatment with dabrafenib and trametinib and the corresponding clinical findings.